Core Insights - Kangchen Pharmaceutical announced a revenue of RMB 1.569 billion for the six months ending June 30, 2025, representing an increase of approximately 23.7% compared to the six months ending June 30, 2024 [1] - The company's profit attributable to equity shareholders for the same period is RMB 498 million, which is an increase of about 24.6% compared to the previous year [1] Financial Performance - Revenue for the six months ending June 30, 2025: RMB 1.569 billion, up 23.7% from the previous year [1] - Profit attributable to equity shareholders for the same period: RMB 498 million, up 24.6% from the previous year [1]

Market Overview - Hong Kong stocks experienced volatility, with the Hang Seng Index closing down 0.21% at 25,122.9 points and a total turnover of 278.2 billion HKD [1] - The Hang Seng China Enterprises Index fell 0.3% to 9,006.23 points, while the Hang Seng Tech Index decreased by 0.67% to 5,542.03 points [1] Blue Chip Performance - China Resources Beer saw a significant increase of 6.24%, closing at 28.28 HKD, contributing 4.24 points to the Hang Seng Index [2] - The company reported a revenue of 23.942 billion RMB, a year-on-year increase of 0.83%, and a net profit attributable to shareholders of 5.789 billion RMB, up 23.04% [2] - Other notable blue chips included Zhongsheng Holdings, which rose 8.29%, and Hansoh Pharmaceutical, which increased by 4.75% [2] Sector Performance - Large tech stocks showed mixed results, with Tencent up 0.94% and Alibaba down 0.25% [3] - AI application stocks performed well, with Zhihu-W rising 23% and Fenbi increasing by nearly 14% [3] - The property management sector was active, with Wanwu Cloud rising 7.19% and Sunac Services increasing by 5.18% [4][5] Earnings Reports - Wanwu Cloud reported a revenue of 18.14 billion RMB, a 3.1% year-on-year increase, and a core net profit of 1.32 billion RMB, up 10.8% [5] - Kancheng Pharmaceutical reported a revenue of 1.569 billion RMB, a 23.7% increase, and a net profit of 498 million RMB, up 24.6% [8] - Li Auto announced a revenue of 24.25 billion RMB, a 174% increase, with a gross margin of 14.1% [9] Notable Stock Movements - Dongfang Zhenxuan experienced a significant drop of 20.89%, closing at 34.32 HKD, following rumors regarding its CEO [12] - Gilead Sciences saw a decline of 15.01% after announcing a share placement and a new share subscription at a discount [13]

智通财经APP讯，康臣药业(01681)发布公告，将于2025年9月19日派发截至2025年6月30日止六个月的中 期股息每股0.33港元。 ...

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事局成員包括執行董事安猛先生、朱荃教授及楊玉川先生；非執行董事張麗華博士；以及獨立非執行董事馮仲實 先生、李義凱教授、李灼光先生及段威武先生。 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 康臣葯業集團有限公司 | | 股份代號 | 01681 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月19日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Kangchen Pharmaceutical, which rose over 7% and reached a new high of 14.59 HKD since its listing [1] - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The net profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] Group 2 - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] - The sales of nephrology product series grew approximately 28.0% compared to the same period last year, with the flagship product, Uremic Clear Granules, maintaining its market leadership [1] - The sales of the women's and children's product series increased by about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]

消息面上，康臣药业今日午间公布截至6月30日止六个月业绩称，期内收入为15.69亿元(人民币，下 同)，同比增约23.7%；公司权益股东应占溢利为4.98亿元，同比增约24.6%，每股基本及摊薄盈利分别 约为0.59元及0.58元。拟派中期股息每股0.33港元。 上半年集团的毛利为12.09亿元，同比增约27.6%，毛利增长主要由于销售增长。整体销售收入的增长主 要由于集团持续致力开拓产品市场以及发展全国各地的销售网络。此外，上半年集团的平均毛利率约为 77.1%，与2024年同期的74.7%相比，增长2.4个百分点，主要由于中药材原材料采购价格下降。(格隆 汇) 康臣药业(1681.HK)午后直线拉升，一度涨9.87%至14.81港元，股价创历史新高，市值超126亿港元。该 股年内已累涨超88%，较今年1月9日盘中创下的年内低点7.05港元已累涨110%。 ...

Core Viewpoint - Kangchen Pharmaceutical reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong business performance and growth potential in the pharmaceutical sector [1] Financial Performance - The company's revenue reached RMB 1.569 billion, representing a year-on-year growth of approximately 23.7% [1] - The profit attributable to equity shareholders was RMB 498 million, showing a year-on-year increase of about 24.6% [1] - Basic and diluted earnings per share were RMB 0.59 and RMB 0.58, respectively [1] - The company proposed an interim dividend of HKD 0.33 per share [1] Gross Margin and Profitability - The group's gross profit increased by approximately 27.6%, with the gross margin rising to 77.1% [1] - The improvement in gross margin was primarily due to sales growth and a decrease in the procurement prices of traditional Chinese medicine raw materials [1] Product Performance - Sales of nephrology product series grew by 28.0%, with Uremic Clear maintaining its leading position [1] - Sales of maternal and pediatric product series increased by 17.5%, becoming the second-largest source of revenue [1] - Sales of medical imaging contrast agents rose by 22.0% [1] - Other product series also recorded varying degrees of growth [1]

上半年，集团的毛利约为12.09元，同比增长27.6%。毛利增长主要是由于销售增长所致。平均毛利率约 为77.1%，同比增长2.4个百分点，主要是由于中药材原材料采购价格下降所致。 【财华社讯】康臣药业(01681.HK)公布，截至2025年6月30日止六个月，集团收入15.69亿元(人民币,下 同)，同比增加23.7%；权益股东应占溢利4.98亿元，同比增加24.6%；每股基本盈利0.59元。拟派中期息 0.33元。 截至发稿，康臣药业涨7.34%，报14.47港元。 本文源自：财华网 ...

Core Viewpoint - Kangchen Pharmaceutical (01681) experienced a significant stock price increase of over 7%, reaching a new high of 14.59 HKD since its listing, following the release of its interim financial results [1] Financial Performance - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] Product Performance - Sales from the nephrology product line grew approximately 28.0% compared to the same period last year, with Uremic Clear Granules (尿毒清) remaining the company's flagship product and maintaining its market leadership [1] - The pediatric and women's health product line saw a sales increase of about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]

格隆汇8月19日｜康臣药业公告，截至2025年6月30日止六个月的收入为人民币15.69亿元，同比增加约 23.7%；权益股东应占溢利为人民币4.98亿元，同比增加约24.6%。 ...